BioLineRx to Report Second Quarter 2013 Results on August 6, 2013
Management to hold a conference call at
The Company will host a conference call on
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com
or www.kcsa.com.
A dial-in replay of the call will be available until
About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of seven clinical stage
candidates: BL-1040, for prevention of pathological cardiac remodeling
following a myocardial infarction, and which has been out-licensed to
Source:
KCSA Strategic Communications
Garth Russell / Todd Fromer
1-212-896-1250
/ 1-212-896-1215
grussell@kcsa.com
/ tfromer@kcsa.com
or
BioLineRx
Ltd.
Tsipi Haitovsky, Public Relations
+972-3-6240871
tsipih@netvision.net.il